C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
US8236761B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 10, 2008 |
| Grant date | Aug 7, 2012 |
| Priority date | — |
| Expiry date | Jan 5, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/044
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis, cancer metastasis, adipogenesis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, including cancer, obesity and conditions associated with obesity, and other disorders, for example, by altering hepatocyte growth factor activity or c-Met receptor activity by administering an angiotensin-like factor that specifically binds to a cell surface c-Met receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.